Posted by Michael Wonder on 22 Aug 2016
Supernus receives FDA tentative approval for expanded label of Trokendi XR to include migraine prophylaxis in adults
19 August 2016 - Supernus Pharmaceuticals today announced that the FDA has granted tentative approval to the Company's supplemental new drug application requesting a label expansion for Trokendi XR to include prophylaxis of migraine headache in adults.
The approval of the sNDA is tentative because the FDA has determined that the drug meets all of the required quality, safety, and efficacy standards for approval, but is subject to the pediatric exclusivity which expires March 28, 2017. Final approval may not be made effective until this exclusivity period has expired.
In addition, the Company announced today that the FDA has granted final approval to expand the label for Trokendi XR for monotherapy treatment of partial onset seizures to include adults and pediatric patients 6 years and older, rather than 10 years and older.
